Search

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

EU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'

 

Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

Thrombocytopenias and Platelet Function Disorders

The SWG was established at the 2003 EHA Congress, which was held in Lyon, France. The group's original focus was thrombocytopenias, but it subsequently expanded its field of interest with the inclusion of platelet function disorders.

Read more

What an EHA Bilateral Collaborative Grant supports

Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.

Read more

What an EHA Innovation Grant supports

Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.

Read more

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more